메뉴 건너뛰기




Volumn 31, Issue 28, 2013, Pages 3592-3599

Contraindicated use of bevacizumab and toxicity in elderly patients with cancer

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

EID: 84891498064     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4857     Document Type: Article
Times cited : (46)

References (36)
  • 1
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
    • (2003) Nat Med , vol.9 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 2
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 3
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 4
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer
    • Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 5
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
    • (2007) N Engl J Med , vol.357 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 7
    • 85024133429 scopus 로고    scopus 로고
    • https://online.epocrates.com/noFrame/show Page.do?method-drugs&MonographId-3619&Active SectionId-10
  • 8
    • 77954651388 scopus 로고    scopus 로고
    • Uncertainty in assessing value of oncology treatments
    • Mullins CD, Montgomery R, Tunis S: Uncertainty in assessing value of oncology treatments. Oncologist 15:58-64, 2010 (suppl 1)
    • (2010) Oncologist , vol.15 , pp. 58-64
    • Mullins, C.D.1    Montgomery, R.2    Tunis, S.3
  • 9
    • 0027645744 scopus 로고
    • Potential for cancer related health services research using a linked Medicare-tumor registry database
    • Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
    • (1993) Med Care , vol.31 , pp. 732-748
    • Potosky, A.L.1    Riley, G.F.2    Lubitz, J.D.3
  • 10
    • 0004299806 scopus 로고    scopus 로고
    • (9th revision). Geneva, Switzerland
    • World Health Organization: International Classification of Disease (9th revision). Geneva, Switzerland, 2008
    • (2008) International Classification of Disease
  • 11
    • 71549137792 scopus 로고    scopus 로고
    • Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer
    • Hershman DL, Buono DL, Malin J, et al: Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 101:1633-1641, 2009
    • (2009) J Natl Cancer Inst , vol.101 , pp. 1633-1641
    • Hershman, D.L.1    Buono, D.L.2    Malin, J.3
  • 12
    • 34547136178 scopus 로고    scopus 로고
    • Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer
    • Du XL, Fang S, Vernon SW, et al: Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660-669, 2007
    • (2007) Cancer , vol.110 , pp. 660-669
    • Du, X.L.1    Fang, S.2    Vernon, S.W.3
  • 13
    • 0022474696 scopus 로고
    • Assessing illness severity: Does clinical judgment work?
    • Charlson ME, Sax FL, MacKenzie CR, et al: Assessing illness severity: Does clinical judgment work? J Chronic Dis 39:439-452, 1986
    • (1986) J Chronic Dis , vol.39 , pp. 439-452
    • Charlson, M.E.1    Sax, F.L.2    MacKenzie, C.R.3
  • 14
    • 0034531923 scopus 로고    scopus 로고
    • Development of a comorbidity index using physician claims data
    • Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
    • (2000) J Clin Epidemiol , vol.53 , pp. 1258-1267
    • Klabunde, C.N.1    Potosky, A.L.2    Legler, J.M.3
  • 15
    • 17144465669 scopus 로고    scopus 로고
    • Measuring complications of cancer treatment using the SEER-Medicare data
    • Potosky AL, Warren JL, Riedel ER, et al: Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV-62-8, 2002
    • (2002) Med Care , vol.40 , pp. IV-8
    • Potosky, A.L.1    Warren, J.L.2    Riedel, E.R.3
  • 16
    • 33644898103 scopus 로고    scopus 로고
    • Increasing trial generalizability
    • Gotay CC: Increasing trial generalizability. J Clin Oncol 24:846-847, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 846-847
    • Gotay, C.C.1
  • 17
    • 80054818006 scopus 로고    scopus 로고
    • Outcomes when cancer treatment is delivered on, or off, a clinical trial: Implications for generalizability of study results
    • Markman M: Outcomes when cancer treatment is delivered on, or off, a clinical trial: Implications for generalizability of study results. Oncology 81:141-142, 2011
    • (2011) Oncology , vol.81 , pp. 141-142
    • Markman, M.1
  • 18
    • 80052286823 scopus 로고    scopus 로고
    • Cancer trials versus the real world in the United States
    • discussion 42-43
    • Al-Refaie WB, Vickers SM, Zhong W, et al: Cancer trials versus the real world in the United States. Ann Surg 254:438-442, 2011; discussion 42-43
    • (2011) Ann Surg , vol.254 , pp. 438-442
    • Al-Refaie, W.B.1    Vickers, S.M.2    Zhong, W.3
  • 19
    • 0038257702 scopus 로고
    • Subtitle B
    • NIH Revitalization Act. Subtitle B:131-133. 1993
    • (1993) NIH Revitalization Act , pp. 131-133
  • 20
    • 33644847203 scopus 로고    scopus 로고
    • Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials
    • Unger JM, Coltman CA Jr, Crowley JJ, et al: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 24:141-144, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 141-144
    • Unger, J.M.1    Coltman, C.A.2    Crowley, J.J.3
  • 21
    • 2642573558 scopus 로고    scopus 로고
    • Participation in cancer clinical trials: Race-, sex-, and agebased disparities
    • Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: Race-, sex-, and agebased disparities. JAMA 291:2720-2726, 2004
    • (2004) JAMA , vol.291 , pp. 2720-2726
    • Murthy, V.H.1    Krumholz, H.M.2    Gross, C.P.3
  • 22
    • 84858843113 scopus 로고    scopus 로고
    • Uptake and economic impact of first-cycle colonystimulating factor use during adjuvant treatment of breast cancer
    • Hershman DL, Wilde ET, Wright JD, et al: Uptake and economic impact of first-cycle colonystimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 30:806-812, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 806-812
    • Hershman, D.L.1    Wilde, E.T.2    Wright, J.D.3
  • 23
    • 80052712426 scopus 로고    scopus 로고
    • Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer
    • Wright JD, Neugut AI, Wilde ET, et al: Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 29:3408-3418, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 3408-3418
    • Wright, J.D.1    Neugut, A.I.2    Wilde, E.T.3
  • 24
    • 84864283129 scopus 로고    scopus 로고
    • Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience
    • Lerose R, Musto P, Aieta M, et al: Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience. Eur J Clin Pharmacol 68:505-512, 2012
    • (2012) Eur J Clin Pharmacol , vol.68 , pp. 505-512
    • Lerose, R.1    Musto, P.2    Aieta, M.3
  • 25
    • 71549119500 scopus 로고    scopus 로고
    • Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention
    • Tsai TT, Maddox TM, Roe MT, et al: Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 302:2458-2464, 2009
    • (2009) JAMA , vol.302 , pp. 2458-2464
    • Tsai, T.T.1    Maddox, T.M.2    Roe, M.T.3
  • 26
    • 67649776649 scopus 로고    scopus 로고
    • Racial differences in definitive breast cancer therapy in older women: Are they explained by the hospitals where patients undergo surgery?
    • Keating NL, Kouri E, He Y, et al: Racial differences in definitive breast cancer therapy in older women: Are they explained by the hospitals where patients undergo surgery? Med Care 47:765-773, 2009
    • (2009) Med Care , vol.47 , pp. 765-773
    • Keating, N.L.1    Kouri, E.2    He, Y.3
  • 27
    • 78650702699 scopus 로고    scopus 로고
    • The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care
    • Freedman RA, Virgo KS, He Y, et al: The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 117:180-189, 2011
    • (2011) Cancer , vol.117 , pp. 180-189
    • Freedman, R.A.1    Virgo, K.S.2    He, Y.3
  • 28
    • 0025327310 scopus 로고
    • Black-white disparities in health care
    • Black-white disparities in health care. JAMA 263:2344-2346, 1990
    • (1990) JAMA , vol.263 , pp. 2344-2346
  • 29
    • 53049099678 scopus 로고    scopus 로고
    • Bevacizumab in advanced cancer, too much or too little?
    • Jirillo A, Vascon F, Giacobbo M: Bevacizumab in advanced cancer, too much or too little? Ann Oncol 19:1817-1818, 2008
    • (2008) Ann Oncol , vol.19 , pp. 1817-1818
    • Jirillo, A.1    Vascon, F.2    Giacobbo, M.3
  • 30
    • 84861309946 scopus 로고    scopus 로고
    • The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy
    • Dawood S, Shaikh AJ, Buchholz TA, et al: The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 118:2780-2786, 2012
    • (2012) Cancer , vol.118 , pp. 2780-2786
    • Dawood, S.1    Shaikh, A.J.2    Buchholz, T.A.3
  • 31
    • 20644432867 scopus 로고    scopus 로고
    • Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
    • Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 3502-3508
    • Hurwitz, H.I.1    Fehrenbacher, L.2    Hainsworth, J.D.3
  • 32
    • 30444449389 scopus 로고    scopus 로고
    • Reform of drug regulation-beyond an independent drug-safety board
    • Ray WA, Stein CM: Reform of drug regulation-Beyond an independent drug-safety board. N Engl J Med 354:194-201, 2006
    • (2006) N Engl J Med , vol.354 , pp. 194-201
    • Ray, W.A.1    Stein, C.M.2
  • 33
    • 0038478965 scopus 로고    scopus 로고
    • Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population
    • Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18, 2002
    • (2002) Med Care , vol.40 , pp. IV-18
    • Warren, J.L.1    Klabunde, C.N.2    Schrag, D.3
  • 34
    • 55549114347 scopus 로고    scopus 로고
    • Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy
    • Smith GL, Smith BD, Buchholz TA, et al: Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 26:5119-5125, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 5119-5125
    • Smith, G.L.1    Smith, B.D.2    Buchholz, T.A.3
  • 35
    • 33745839859 scopus 로고    scopus 로고
    • Late gastrointestinal toxicity after radiation for prostate cancer
    • Giordano SH, Lee A, Kuo YF, et al: Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 107:423-432, 2006
    • (2006) Cancer , vol.107 , pp. 423-432
    • Giordano, S.H.1    Lee, A.2    Kuo, Y.F.3
  • 36
    • 33747400905 scopus 로고    scopus 로고
    • Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer
    • Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
    • (2006) J Natl Cancer Inst , vol.98 , pp. 1108-1117
    • Hassett, M.J.1    O'Malley, A.J.2    Pakes, J.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.